نتایج جستجو برای: 3 kinase

تعداد نتایج: 1981504  

2017
James E Casanova Bettina Winckler

Endosome maturation requires a coordinated change in the Rab GTPase and phosphoinositide composition of the endosomal membrane. In this issue, Liu et al. (2017. J. Cell Biol. https://doi.org/10.1083/jcb.201705151) identify WDR91 as a ubiquitous Rab7 effector that inhibits phosphatidylinositol 3-kinase activity on endosomes and is critical for endosome maturation, viability, and dendrite growth ...

Journal: :iranian journal of pharmaceutical research 0
ramin shekarriz md, board certified hematologist-oncologist, assistant professor, department of hematology-oncology, cancer research center, imam khomeini hospital, mazandaran university of medical sciences, sari, iran neda koulaeinejad pharmd, resident of clinical pharmacy, faculty of pharmacy, mazandaran university of medical sciences, sari, iran anahita nosrati md, board certified pathologist, assistant professor, department of pathology, imam khomeini hospital, mazandaran university of medical sciences, sari, iran ebrahim salehifar pharmd, board certified clinical pharmacist, associated professor, department of clinical pharmacy, pharmaceutical research center, mazandaran university of medical sciences, sari, iran

sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. it was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and advanced pancreatic neuroendocrine tumors. it has several adverse reactions on multi organ systems including hematologic system. although the neutropenia and thrombocytopenia commonly happens as gra...

Journal: :international journal of hematology-oncology and stem cell research 0
gholamreza bahoush pediatric hematology-oncology department, ali-asghar children's hospital, iran university of medical sciences, tehran, iran mardavizh albouyeh pediatric hematology-oncology department, shohada general hospital, shahid-beheshti university of medical sciences, tehran, iran parvaneh vossough 1pediatric hematology-oncology department, ali-asghar children's hospital, iran university of medical sciences, tehran, iran

introduction: imatinib mesylate is a selective inhibitor of tk and is considered now to be the frontline therapeutic agent during the chronic phase of cml. we have evaluated the efficacy of it on children with chronic-phase of cml. patients and methods: in a clinical trial study over the past 3 years, 14 patients (8 females and 6 males, 2.5-14 years old) were admitted with a diagnosis of cml. s...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید